Compare Merck & Co., Inc. (MRK) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Motorola Solutions Inc — how do they compare? Merck & Co., Inc. trades at $145.83 (market cap $351.28B), while Motorola Solutions Inc trades at $443.51 (market cap $74.00B). The key difference: Merck & Co., Inc. is far larger — about 4.7× Motorola Solutions Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Motorola Solutions Inc for 100 Days on average.
| MRK | MSI | |
|---|---|---|
Market Cap | $351.28B | $74.00B |
Volume | 7,969,665 | 722,147 |
Sector | Health | Technology |
52-Week High | $156.43 | $491.24 |
52-Week Low | $82.49 | $363.83 |
Typical Hold Time | 98 Days | 100 Days |
Enterprise Value | $398.04B | $82.90B |
Dividend Yield | 2.39% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
MSI trades at $444.18, down 0.96% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.41 surpassing the $3.85 estimate. Revenue growth has been steady, reaching $11.68 billion in 2025, and the firm recently announced a $2 billion share repurchase increase and a $139 million public safety contract in Louisiana.
The outlook remains positive with a consensus price target of $525.86, implying 18% upside, supported by a 70.59% buy rating from analysts. Risks include elevated valuation multiples, such as a P/E of 35.23, and significant investing cash outflows for acquisitions, which pressured net cash flow to -$937 million in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
